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Abstract
Background: The response of serum cholesterol to diet may be affected by the apolipoprotein E
(APOE) ε2/ε3/ε4 polymorphism, which also is a significant predictor of variation in the risk of
coronary heart disease (CHD) and CHD death. Here, we test the hypothesis that the APOE
polymorphism may modulate the cholesterol-raising effect of coffee.
Objective: We determined the effect of a coffee abstention period and a daily intake of 600 mL
coffee on serum cholesterol and triglycerides with respect to the APOE polymorphism.
Design: 121 healthy, non-smoking men (22%) and women (78%) aged 29–65 years, took part in a
study with four intervention periods: 1 and 3) a coffee free period of three weeks, 2 and 4) 600 mL
coffee/day for four weeks.
Results: APOE ε2 positive individuals had significantly lower total cholesterol concentration at
baseline (4.68 mmol/L and 5.28 mmol/L, respectively, p = 0.01), but the cholesterol-raising effect
of coffee was not influenced significantly by APOE allele carrier status.
Conclusions: The APOE ε 2 allele is associated with lower serum cholesterol concentration.
However, the APOE polymorphism does not seem to influence the cholesterol-raising effect of
coffee.
Introduction
Apolipoprotein E (apoE) is a structural component of trig-
lyceride-rich lipoproteins, chylomicrons, very-low-density
lipoproteins (VLDL), and high-density-lipoproteins
(HDL) [1]. Variation in the APOE gene sequence results in
the 3 common alleles (ε2, ε3 and ε4), which can produce
6 different genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4
and ε4/ε4). The ε2, ε3 and ε4 alleles encode three distinct
forms of apoE (E2, E3 and E4) and have approximate fre-
quencies of 8%, 77%, and 15%, respectively, in white
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populations [2]. ApoE3 seems to be the normal isoform
in all known functions, while apoE4 and apoE2 can each
be dysfunctional [3,4]. In most populations, individuals
with the APOE ε2 allele display lower levels of plasma
cholesterol compared with individuals carrying the APOE
ε3  allele, whereas individuals with the APOE  ε4  allele
show higher levels of plasma cholesterol, especially LDL-
cholesterol [1,2,5]. Subjects with APOE ε3/ε4 and ε4/ε4
genotypes absorb cholesterol effectively and have higher
non-fasting serum triglyceride values than ε4 negative
individuals [6,7]. The allelic variation in the APOE gene is
shown to be a significant predictor of variation in the risk
of coronary heart disease (CHD) and CHD death [2-4,8-
10], but the results from an extensive prospective study
showed no associations [11]. Both the MONICA Project
[12] and the Scandinavian Simvastatin Survival Study [13]
suggest an increased risk of CHD for individuals carrying
the APOE ε4 allele. The APOE ε4 allele is also considered
a strong risk factor for Alzheimer's disease [14-16].
The serum cholesterol-raising effect of coffee is due to the
diterpenes kahweol and cafestol [17]. Earlier studies have
shown a cholesterol-raising effect mainly of unfiltered
coffee, because a major part of the diterpenes is retained
by a paper filter [18-20]. A recent trial, however, indicates
that filtered coffee has a more pronounced serum choles-
terol-raising effect than previously anticipated [21]. This
finding was further corroborated in a randomized inter-
vention study, where we demonstrated a considerable
cholesterol-raising effect of filtered coffee [22]. In the
study two coffee abstention periods were associated with
a significant decline in serum cholesterol of 0.22 and 0.36
mmol/L, respectively, while 600 mL filtered coffee a day
during two different periods increased serum cholesterol
by 0.25 and 0.15 mmol/L, respectively. Here, we test the
hypothesis that these effects might be modulated by the
APOE ε2/ε3/e4 polymorphism.
Subjects and methods
Trial design
The study was organised as a prospective, controlled study
with four consecutive trial periods. The first and third
periods were 3 weeks of total coffee abstention. The sec-
ond and fourth period consisted of 4 weeks with the sub-
jects consuming 600 mL filter brewed coffee/day.
The main outcome or effect variable was total serum cho-
lesterol and the effect was assessed as the difference
between the measurements at the beginning and the end
of the coffee free periods (coffee abstention) and the dif-
ference between measurements at the beginning and at
the end of the four weeks of coffee consumption (Figure
1). Trial duration of 3–4 weeks has previously been shown
to be sufficient to get an effect of coffee on serum choles-
terol [21,23].
Subjects and procedure
Participants were recruited by advertising in Gothenburg's
major newspaper. Inclusion criteria were age-range 30–65
years, free from clinically recognized chronic diseases,
such as cardiovascular diseases, cancer, renal disorders,
liver disease and diabetes mellitus. The participants were
required to be free from anti-epileptic or cholesterol low-
ering drugs, and had been using coffee on a regular basis
for at least five years and were currently non-smokers (at
least for the last six months).
Study design Figure 1
Study design
3 weeks of 4 weeks of coffee 3 weeks of  4 weeks of coffee
coffee abstention consumption (600mL/day) coffee abstention  consumption (600mL/day)
w0 w1 w2 w3 w4 w5 w6 w7 w8 w9 w10 w11 w12 w13 w14
1
BS
2 BS   BS  BS  BS 
1w = week
2 BS = Blood samples: serum cholesterol, serum HDL cholesterol, serum triglycerides, serum Lp(a)Lipids in Health and Disease 2004, 3:26 http://www.lipidworld.com/content/3/1/26
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During the coffee drinking periods the participants were
instructed to drink about 600 mL filter brewed coffee/day
(4 cups), according to standardised measures. The coffee
was provided to guarantee that they were all exposed to
the same brand and quality of filter brewed coffee. All par-
ticipants also got the same kind of standardised coffee fil-
ter and measuring spoon.
The coffee filters used were of the brand Euro-Shopper,
made by Indupa N.V., Zaventem, Belgium. Divergence
from the 4 cups was reported. The participants were
allowed to drink tea and other caffeine containing bever-
ages during the coffee-free periods.
Effect variables
Non-fasting blood samples were drawn at inclusion and
at three, seven, ten and fourteen weeks after start of the
study. Prior to analysis, prepared serum was stored at -
70°C.
The blood samples were analysed for blood lipids (total
cholesterol, HDL cholesterol, triglycerides, lipoprotein(a)
(Lp(a)) and urate in serum. Serum cholesterol and triglyc-
erides were determined by an enzymatic procedure on a
Hitachi 917 analyzer. HDL cholesterol was determined
enzymatically after precipitation of VLDL, LDL and chy-
lomicrones by α-cyklodextrinsulphate and dextransul-
phate. Determination of Lp(a) was done by the method
Tint Elize Lp(a) of Biopool International. Serum urate was
analysed by Hitachi 917 autoanalyser. Body Mass Index
(BMI; kg/m2) was recorded once during the study. Blood
pressure was recorded by manual device and EKG and
heart rate were recorded at all five visits.
The dietary habits were assessed by dietary frequency
questionnaires at the beginning of the study. A follow-up
survey with special emphasis on changes in food habits
during the four different periods was undertaken. The die-
tary questionnaire was based upon a Norwegian version,
which has been used in a number of previous studies [24].
Genotype Analysis
APOE genotypes were determined by solid-phase minise-
quencing as previously described by Blennow et al [25].
Statistical methods
All analyses were performed using the SAS©software ver-
sion 8. Signed rank test was used to test differences in the
groups. Wilcoxon rank sum test was used to test differ-
ences at baseline and differences between the groups. The
mean was used as location measure and measures of vari-
ation were described in terms of standard deviation. P-val-
ues < 0.05 were considered statistically significant.
Results
A total of 156 persons responded to the advertisement
and of these 124 fulfilled the criteria and were able to take
part. Three persons decided to withdraw during the study,
leaving a total of 121 participants. One person was not
able to take part during the first two periods and five per-
sons were not able to take part in the last two periods,
which resulted in 120 participants in the first trial period
and 116 in the subsequent trial period.
Table 1: APOE genotype and allele frequency, n = 121
n%
ε2/ε2 21 . 7
ε2/ε3 97 . 4
ε2/ε4 21 . 7
ε3/ε3 69 57.0
ε3/ε4 36 29.8
ε4/ε4 32 . 5
ε2 15 6.2
ε3 183 75.6
ε4 44 18.2
Table 2: Serum cholesterol concentration (mmol/L) at baseline 
and after two 3-week periods of coffee abstention (week 0 – 3 
and week 7 – 10) for APOE ε2-positive (n = 13) and APOE ε2-
negative (n = 108) individuals
APOE ε2-
positive
APOE ε2-
negative
p
n = 13 n = 107/103 a
First trial period
week 0 4.68 (0.80) 5.28 (0.93) 0.01b
week 3 4.49 (0.71) 5.05 (0.90)
diff week 0–3 -0.18 (0.24) -0.23 (0.55) 0.30 
c
p (diff 0–3) 0.02 d <0.0001d
Second trial period
week 7 4.52 (0.71) 5.34 (0.93)
week 10 4.34 (0.64) 4.95 (0.89)
week 7–10 -0.18 (0.41) -0.39 (0.55) 0.08 
c
p (diff 7–10) 0.13 <0.0001d
a 107 participants in the first trial period and 103 participants in the 
second trial period
b Significant difference between APOE ε2-positive and APOE ε2-
negative at baseline, Wilcoxon rank sum test
c No significant difference between APOE ε2-positive and APOE ε2-
negative in differences between week 0–3 or week 7–10, Wilcoxon 
rank sum test
d Significant difference between week 0–3 for the APOE ε2-positive 
group and between week 0–3 and week 7–10 for the APOE ε2-
negative group, Signed rank testLipids in Health and Disease 2004, 3:26 http://www.lipidworld.com/content/3/1/26
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Genotype frequencies
The APOE allele frequencies were 6.1% for the ε2 allele,
75.6% for the ε3 allele and 18.2% for the ε4 allele. This
distribution agrees well with those reported in other pop-
ulations in northern Europe [2,3]. Genotype and allele
frequencies for the APOE  polymorphism are given in
Table 1.
Serum cholesterol concentrations according to genotype 
and coffee exposure
Individual APOE genotypes (six subgroups, Table 1) did
not influence baseline values or coffee-induced changes in
serum cholesterol, serum HDL cholesterol, serum triglyc-
erides or serum Lp(a), possibly due to a small sample size
(data not shown). ε4-positive individuals had similar
serum cholesterol levels and coffee-induced changes in
cholesterol concentration as ε4-negative individuals (data
not shown). However, when grouping ε2-positive indi-
viduals it was revealed that these displayed significantly
lower cholesterol at baseline (Table 2). There was a signif-
icant difference in cholesterol decrease between week 0
and 3 for both groups. There was no difference between
the two groups regarding the cholesterol decrease in the
first coffee abstention period but there was a significant
difference in cholesterol decrease in the second coffee
abstention period, where ε2-negative individuals dis-
played a larger decrease in cholesterol (Table 2).
Coffee consumption resulted in a significant cholesterol
increase in the ε2-negative group in both trial periods (w
3–7 and w 10–14), but not in the ε2-positive group (Table
3). There were no differences between the ε2-positive and
the ε2-negative group according to baseline characteristics
as sex, age, body mass index (BMI) and coffee consump-
tion prior to the study (Table 4).
Dietary monitoring and compliance
The dietary survey did not reveal any important changes
during the four intervention periods [22]. Coffee con-
sumption or non-compliance was reported by six persons
during the first coffee abstention period (mean 1.8 cups/
period), whereas four persons reported coffee consump-
tion in the second coffee abstention period (mean 0.7
cups/period).
Discussion
Subjects with different APOE  genotypes differ in the
absorption efficiency of cholesterol from the intestine, in
the synthesis rates of cholesterol and bile acids, and in the
production of LDL apoprotein B [3,26]. This suggests that
the response of serum cholesterol to diet may be affected
by the APOE e2/e3/e4 polymorphism [27,28]. One previ-
ous study examined the effect of purified cafestol on
serum lipids in relation to the APOE polymorphism [26]
and found that responses of LDL-cholesterol to cafestol
were slightly smaller among carriers of the APOE ε4 allele.
Here, we investigate for the first time the possible influ-
ence of the APOE polymorphism on the cholesterol-rais-
ing effect of filtered coffee.
APOE ε4-positive individuals did not differ significantly
from ε4-negative individuals with regard to baseline cho-
lesterol concentration or coffee-induced changes in cho-
lesterol concentration. However, we confirm that ε2-
positive individuals display significantly lower cholesterol
levels at baseline than ε2-negative individuals. A tendency
was seen that ε2-positive individuals might be partly pro-
Table 3: Serum cholesterol concentration (mmol/L) after two 4-
week periods of coffee consumption (week 3 – 7 and week 10 – 
14) for APOE ε2-positive (n = 13) and APOE ε2-negative (n = 108) 
individuals
APOE ε2-positive APOE ε2-negative p
n = 13 n = 107/103 a
First trial period
week 3 4.49 (0.71) 5.05 (0.90)
week 7 4.52 (0.71) 5.34 (0.93)
diff week 3–7 0.03 (0.57) 0.29 (0.57) 0.0
9 b
p (diff 3–7) 0.70 <0.0001 c
Second trial period
week 10 4.34 (0.64) 4.95 (0.89)
week 14 4.54 (0.84) 5.09 (0.85)
diff week 10–14 0.20 (0.47) 0.14 (0.59) 0.3
7 b
p (diff 10–14) 0.15 0.009 c
a 107 participants in the first trial period and 103 participants in the 
second trial period
b No significant difference between 2-positive and 2-negative in 
differences between week 3–7 or week 10–14, Wilcoxon rank sum 
test
c Significant difference between week 0–3 and week 7–10 for the 
APOE ε2-negative group, Signed rank test
Table 4: Baseline characteristics for APOE ε2-positive (n = 13) 
and APOE ε2-negative (n = 108) individuals
APOE ε2-positive APOE ε2-negative p
n = 13 n = 108
Sex (% women) 77 79 ns a
Age (years) 46.6 48.7 0.44 b
BMI (kg/m2) 2 5 . 72 5 . 80 . 8 7   b
Coffee 
consumption 
(cups/day)
4.3 3.7 0.12 b
a No significant difference between APOE ε2-positive and APOE ε2-
negative at baseline, Chi square test
b No significant difference between APOE ε2-positive and APOE ε2-
negative at baseline, Wilcoxon rank sum testPublish with BioMed Central    and   every 
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tected from the cholesterol increasing effect of coffee con-
sumption. This was, however, only seen in the first trial
period and will require further investigations. In conclu-
sion, the APOE ε2/ε3/ε4 polymorphism is not a strong
modulator of the cholesterol-increasing effect of coffee.
Other genes should be discussed and further investigation
is needed to see if there is a genetic factor in the choles-
terol-raising effect of coffee.
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